Oncology Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Oncology Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Group of cells that lose contact inhibition growth mechanism leads to development of tumor, which is potent to grow infinitely at its origin or can invade into blood stream and lead to tumor at different sites. Based on the location ability of tumor cancer, it is classified as benign tumor or malignant tumor, respectively. The global oncology drugs market is segmented by drug type, by cancer type, and by distribution channel. Based on the drug type, the market is segmented into cytotoxic drugs, targeted drugs, and hormonal drug. Targeted drugs specifically target cancerous cells, which helps in reducing the side effects of the drugs. This in turn propels growth of targeted drugs segment.
Market Dynamics
Increasing drug approvals and robust pipeline for novel therapeutic agents are some of the key factors driving the oncology drugs market growth. For instance, in August 2021, Tisagenlecleucel (Kymriah), a drug developed by Novartis was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and young adults with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). Moreover, increasing prevalence of various types of cancer is also fueling the oncology drugs market growth. For instance, according to a report by National Cancer Institute, 2016, around 16.8 million new cases of cancer are diagnosed in the U.S. every year, with around 595,690 deaths from the disease and the number of people with cancer is expected to increase to 19 million by 2028.
However, high cost of cancer drugs and adoption of alternative treatment options such as surgery and radiation therapy are major factors hindering the oncology drugs market growth. Several blockbuster oncology drugs in the market are expected to lose patent during 2018-2020, which is turn acts as an opportunities for emerging players in the global oncology drugs market.

Key features of the study:
This report provides in-depth analysis of the oncology drugs market and its application, market size (US$ Million) and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer AG, and Amgen Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
The global oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of oncology drug, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the oncology drugs market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Oncology Drugs Market, By Drug Type:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
Global Oncology Drugs Market, By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
Global Oncology Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oncology Drugs Market, By Region:
North America
By Drug Class:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
By Drug Class:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Others
Hormonal Drugs
Ovarian Function Blockers
Estrogen Production Blockers
Estrogen’s Effect Blockers
Selective Estrogen Receptor Modulators (SERMs)
Others
By Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Bladder Cancer
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
North Africa
Central Africa
South Africa
Company Profiles
Hoffmann-La Roche AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Novartis International AG
Celgene Corporation
Johnson & Johnson
Bristol-Myers Squibb
Pfizer Inc.
Merck & Co.
Eli Lilly and Company
AbbVie, Inc.
AstraZeneca plc.
Bayer AG
Amgen Inc.

Strategies “*” marked represents similar segmentation in other categories in the respective section.